Table 1.
Clinical characteristics of the surgical resection patients vs the transarterial chemoembolization patients
| Variable | Surgical resection (n = 36) | TACE (n = 107) | P value |
| Age (yr) | 54.3 ± 8.6 | 61.2 ± 9.3 | < 0.001 |
| Gender (male:female) | 34:2 | 86:21 | 0.047 |
| Platelet (k/mm3) | 153.4 ± 53.9 | 121.0 ± 51.8 | 0.002 |
| Albumin (g/dL) | 4.05 ± 0.50 | 3.93 ± 0.48 | 0.203 |
| ALT (IU/L) | 36.4 ± 15.8 | 59.0 ± 40.4 | 0.001 |
| AST (IU/L) | 41.2 ± 25.8 | 53.2 ± 44.7 | 0.130 |
| HBsAg | 28 (77.8) | 67 (62.6) | 0.099 |
| Clinical liver cirrhosis | 20 (55.6) | 100 (93.5) | < 0.001 |
| Tumor number | 0.549 | ||
| 2 | 30 (83.3) | 90 (84.1) | |
| 3 | 6 (16.7) | 17 (15.9) | |
| Main tumor size (cm) | 0.005 | ||
| < 3 | 19 (52.8) | 17 (47.2) | |
| ≥ 3 | 29 (27.1) | 78 (72.9) | |
| AFP > 1000 IU/mL | 2 (5.6) | 8 (7.5) | 0.696 |
Data are expressed as absolute n (%) or mean ± SD. M: Male; F: Female; TACE: Transarterial chemoembolization; ALT: Alanine aminotransferase (reference range, 5-46 IU/L); AST: Aspartate aminotransferase (reference range, 13-34 IU/L); HBsAg: Hepatitis B surface antigen; AFP: α-fetoprotein.